Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€33.31
09.07.21
-
09.07.22
0.27%
09.07.21

Top 10 in its market
Small cyclical dependencies
Gilbert 
09.07.21 0%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€490.00
08.07.21
-
08.07.22
21.00%
08.07.22

Saftman 
08.07.21 50%
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€142.86
08.07.21
-
08.07.22
22.71%
08.07.22

Saftman 
08.07.21 50%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€57.97
08.07.21
-
08.07.22
5.97%
08.07.22

Sargnagel 
08.07.21 50%
buy
AbbVie Inc.

Start price
Target price
Perf. (%)
€98.99
08.07.21
-
08.07.22
50.06%
08.07.22

Saftman 
08.07.21 50%
buy
Zoetis Inc. A

Start price
Target price
Perf. (%)
€165.05
08.07.21
-
08.07.22
7.24%
08.07.22

Prof 
08.07.21 50%
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€33.21
08.07.21
€55.00
08.07.22
29.12%
18.02.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
gerihouse 
08.07.21 50%
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€142.86
08.07.21
€177.00
08.07.22
22.71%
08.07.22

gerihouse 
08.07.21 50%
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€158.36
17.06.21
€165.00
17.06.22
59.60%
18.06.22

Could be worthwhile Investment >10% per year
melinda 
17.06.21 50%
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€320.85
08.06.21
€330.00
08.06.22
-41.88%
08.06.22

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Top 10 in its market
Well known brand
tbackenh 
08.06.21 80%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€56.02
06.04.21
€60.00
06.04.22
3.82%
01.07.21

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Traumtanz 
06.04.21 70%
sell
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€152.98
25.03.21
€140.00
25.09.21
25.83%
28.06.21

Could be worthwhile Investment >10% per year
Known brand
Medium risks for its business
overvalued
Snowman 
25.03.21 50%
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€136.62
24.03.21
€145.00
24.03.22
-1.26%
09.04.21

Known brand
Future proof or reliable business model
Medium risks for its business
phonebroker 
24.03.21 50%
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€29.35
15.03.21
€50.00
15.03.22
43.43%
09.11.21

Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Snowman 
15.03.21 80%
buy
Zoetis Inc. A

Start price
Target price
Perf. (%)
€130.34
27.02.21
-
27.02.22
37.81%
20.01.22

Innovative
Medium risks for its business
Top 10 in its market
Future proof or reliable business model
Troubadour 
27.02.21 50%
buy
Incyte Corp.

Start price
Target price
Perf. (%)
€64.63
25.02.21
€70.00
3.84%
08.03.21

Could be worthwhile Investment >10% per year
Traumtanz 
25.02.21 50%
sell
Incyte Corp.

Start price
Target price
Perf. (%)
€67.64
24.02.21
-
24.02.22
-12.39%
25.11.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
SpringheelJack 
24.02.21 50%
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€138.90
05.02.21
-
31.12.21
0.09%
29.03.21

Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative
Gilbert 
05.02.21 50%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€54.79
27.01.21
-
27.01.22
6.17%
28.07.21

Mori8 
27.01.21 50%
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€173.98
25.01.21
€250.00
25.01.22
23.00%
17.01.22

Top 10 in its market
Could be worthwhile Investment >10% per year
High dividend yield expected
Innovative
gerihouse 
25.01.21 90%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€463.95
25.01.21
€500.00
25.01.22
15.42%
26.01.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
WatchMen 
25.01.21 0%
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€134.68
20.01.21
€144.00
0.89%
02.02.21

Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative
Gilbert 
20.01.21 60%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€55.31
19.01.21
€67.00
19.01.22
14.53%
20.01.22

Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Snowman 
19.01.21 50%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.89
09.01.21
€68.00
09.01.22
8.15%
30.10.21

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
RudolfL 
09.01.21 60%
sell
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€48.93
05.01.21
-
05.01.22
10.78%
03.06.21

Could be worthwhile Investment >10% per year
Capable Management
Innovative
Market Leader or Top 3
Trip 
05.01.21 50%